Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADXS11-001 + Pemetrexed in HPV+ NSCLC
NCT02531854Phase 2Withdrawn
- Sponsor
- Advaxis, Inc.
- Start
- Dec 2018
- Primary completion
- Mar 2019
- Modality
- Gene Editing, Gene Silencing, Vaccines & Immunotherapeutics
01
Overview
A Phase 2 trial of axalimogene filolisbac in non-small cell lung carcinoma (NSCLC), sponsored by Advaxis, Inc.. Planned start Dec 2018; status: withdrawn.
02
Drugs
axalimogene filolisbac
03
Conditions
non-small cell lung carcinoma (NSCLC)
Beyond the preview
Go deeper on NCT02531854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02531854.